| Date | Source | Headline |
|---|---|---|
| 24th Mar 2026 7:00 am | MFN | Notice to Annual General Meeting in BioInvent International AB |
| 26th Feb 2026 7:00 am | MFN | BioInvent International AB: Year-end report January 1 - December 31, 2025 |
| 5th Jan 2026 6:30 am | MFN | BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA® (pembrolizumab) in Recurrent Ovarian Cancer |
| 8th Dec 2025 1:00 pm | MFN | BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025 |
| 7th Dec 2025 1:00 pm | MFN | BioInvent Presents Promising Early Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025 |